Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma Article Swipe

PDF

Dominic E. A. Brittain , Peter D’Andrea , Emilie Gruen , Motoi Hosoe , DK Jain , Juergen Jauernig , Abhijit Pethe , Emil Scosyrev , Ana-Maria Tanase , Hanns-Christian Tillmann ·

YOU? · · 2022 · Open Access · · DOI: https://doi.org/10.1007/s12325-021-02025-w

Related Topics

Concepts

Indacaterol Mometasone furoate Medicine Inhaler Asthma Fixed-dose combination Pharmacology Corticosteroid Internal medicine Bronchodilator

Metadata

Type: review
Language: en
Landing Page: https://doi.org/10.1007/s12325-021-02025-w
PDF: https://link.springer.com/content/pdf/10.1007/s12325-021-02025-w.pdf
OA Status: hybrid
Cited By: 11
References: 27
Related Works: 10
OpenAlex ID: https://openalex.org/W4206970869

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4206970869

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1007/s12325-021-02025-w

Digital Object Identifier
Title: A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma

Work title
Type: review

OpenAlex work type
Language: en

Primary language
Publication year: 2022

Year of publication
Publication date: 2022-01-24

Full publication date if available
Authors: Dominic E. A. Brittain, Peter D’Andrea, Emilie Gruen, Motoi Hosoe, DK Jain, Juergen Jauernig, Abhijit Pethe, Emil Scosyrev, Ana-Maria Tanase, Hanns-Christian Tillmann

List of authors in order
Landing page: https://doi.org/10.1007/s12325-021-02025-w

Publisher landing page
PDF URL: https://link.springer.com/content/pdf/10.1007/s12325-021-02025-w.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: hybrid

Open access status per OpenAlex
OA URL: https://link.springer.com/content/pdf/10.1007/s12325-021-02025-w.pdf

Direct OA link when available
Concepts: Indacaterol, Mometasone furoate, Medicine, Inhaler, Asthma, Fixed-dose combination, Pharmacology, Corticosteroid, Internal medicine, Bronchodilator

Top concepts (fields/topics) attached by OpenAlex
Cited by: 11

Total citation count in OpenAlex
Citations by year (recent): 2025: 2, 2023: 7, 2022: 2

Per-year citation counts (last 5 years)
References (count): 27

Number of works referenced by this work
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4206970869
doi	https://doi.org/10.1007/s12325-021-02025-w
ids.doi	https://doi.org/10.1007/s12325-021-02025-w
ids.openalex	https://openalex.org/W4206970869
fwci	1.97446006
type	review
title	A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
biblio.issue	6
biblio.volume	39
biblio.last_page	2378
biblio.first_page	2365
topics[0].id	https://openalex.org/T10051
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	1.0
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2737
topics[0].subfield.display_name	Physiology
topics[0].display_name	Asthma and respiratory diseases
topics[1].id	https://openalex.org/T11651
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9993000030517578
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2740
topics[1].subfield.display_name	Pulmonary and Respiratory Medicine
topics[1].display_name	Inhalation and Respiratory Drug Delivery
topics[2].id	https://openalex.org/T12418
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9965999722480774
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2740
topics[2].subfield.display_name	Pulmonary and Respiratory Medicine
topics[2].display_name	Respiratory and Cough-Related Research
is_xpac	False
apc_list.value	3390
apc_list.currency	EUR
apc_list.value_usd	4390
apc_paid.value	3390
apc_paid.currency	EUR
apc_paid.value_usd	4390
concepts[0].id	https://openalex.org/C2778884479
concepts[0].level	4
concepts[0].score	0.9466346502304077
concepts[0].wikidata	https://www.wikidata.org/wiki/Q425654
concepts[0].display_name	Indacaterol
concepts[1].id	https://openalex.org/C2781348165
concepts[1].level	3
concepts[1].score	0.8402062654495239
concepts[1].wikidata	https://www.wikidata.org/wiki/Q1044248
concepts[1].display_name	Mometasone furoate
concepts[2].id	https://openalex.org/C71924100
concepts[2].level	0
concepts[2].score	0.8279763460159302
concepts[2].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[2].display_name	Medicine
concepts[3].id	https://openalex.org/C2780261241
concepts[3].level	3
concepts[3].score	0.5691577792167664
concepts[3].wikidata	https://www.wikidata.org/wiki/Q1394363
concepts[3].display_name	Inhaler
concepts[4].id	https://openalex.org/C2776042228
concepts[4].level	2
concepts[4].score	0.5242034196853638
concepts[4].wikidata	https://www.wikidata.org/wiki/Q35869
concepts[4].display_name	Asthma
concepts[5].id	https://openalex.org/C2776623344
concepts[5].level	2
concepts[5].score	0.5117506980895996
concepts[5].wikidata	https://www.wikidata.org/wiki/Q5456317
concepts[5].display_name	Fixed-dose combination
concepts[6].id	https://openalex.org/C98274493
concepts[6].level	1
concepts[6].score	0.4051735997200012
concepts[6].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[6].display_name	Pharmacology
concepts[7].id	https://openalex.org/C2776804153
concepts[7].level	2
concepts[7].score	0.37750279903411865
concepts[7].wikidata	https://www.wikidata.org/wiki/Q210420
concepts[7].display_name	Corticosteroid
concepts[8].id	https://openalex.org/C126322002
concepts[8].level	1
concepts[8].score	0.2719956636428833
concepts[8].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[8].display_name	Internal medicine
concepts[9].id	https://openalex.org/C2781018748
concepts[9].level	3
concepts[9].score	0.10268798470497131
concepts[9].wikidata	https://www.wikidata.org/wiki/Q927234
concepts[9].display_name	Bronchodilator
keywords[0].id	https://openalex.org/keywords/indacaterol
keywords[0].score	0.9466346502304077
keywords[0].display_name	Indacaterol
keywords[1].id	https://openalex.org/keywords/mometasone-furoate
keywords[1].score	0.8402062654495239
keywords[1].display_name	Mometasone furoate
keywords[2].id	https://openalex.org/keywords/medicine
keywords[2].score	0.8279763460159302
keywords[2].display_name	Medicine
keywords[3].id	https://openalex.org/keywords/inhaler
keywords[3].score	0.5691577792167664
keywords[3].display_name	Inhaler
keywords[4].id	https://openalex.org/keywords/asthma
keywords[4].score	0.5242034196853638
keywords[4].display_name	Asthma
keywords[5].id	https://openalex.org/keywords/fixed-dose-combination
keywords[5].score	0.5117506980895996
keywords[5].display_name	Fixed-dose combination
keywords[6].id	https://openalex.org/keywords/pharmacology
keywords[6].score	0.4051735997200012
keywords[6].display_name	Pharmacology
keywords[7].id	https://openalex.org/keywords/corticosteroid
keywords[7].score	0.37750279903411865
keywords[7].display_name	Corticosteroid
keywords[8].id	https://openalex.org/keywords/internal-medicine
keywords[8].score	0.2719956636428833
keywords[8].display_name	Internal medicine
keywords[9].id	https://openalex.org/keywords/bronchodilator
keywords[9].score	0.10268798470497131
keywords[9].display_name	Bronchodilator
language	en
locations[0].id	doi:10.1007/s12325-021-02025-w
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S27230875
locations[0].source.issn	0741-238X, 1865-8652
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	0741-238X
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Advances in Therapy
locations[0].source.host_organization	https://openalex.org/P4310320330
locations[0].source.host_organization_name	Adis, Springer Healthcare
locations[0].source.host_organization_lineage	https://openalex.org/P4310320330
locations[0].license	cc-by-nc
locations[0].pdf_url	https://link.springer.com/content/pdf/10.1007/s12325-021-02025-w.pdf
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id	https://openalex.org/licenses/cc-by-nc
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Advances in Therapy
locations[0].landing_page_url	https://doi.org/10.1007/s12325-021-02025-w
locations[1].id	pmh:oai:pubmedcentral.nih.gov:9122880
locations[1].is_oa	True
locations[1].source.id	https://openalex.org/S2764455111
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	PubMed Central
locations[1].source.host_organization	https://openalex.org/I1299303238
locations[1].source.host_organization_name	National Institutes of Health
locations[1].source.host_organization_lineage	https://openalex.org/I1299303238
locations[1].license	other-oa
locations[1].pdf_url
locations[1].version	submittedVersion
locations[1].raw_type	Text
locations[1].license_id	https://openalex.org/licenses/other-oa
locations[1].is_accepted	False
locations[1].is_published	False
locations[1].raw_source_name	Adv Ther
locations[1].landing_page_url	https://www.ncbi.nlm.nih.gov/pmc/articles/9122880
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5030207540
authorships[0].author.orcid
authorships[0].author.display_name	Dominic E. A. Brittain
authorships[0].countries	CH
authorships[0].affiliations[0].institution_ids	https://openalex.org/I1283582996
authorships[0].affiliations[0].raw_affiliation_string	Novartis Pharma AG, Basel, Switzerland
authorships[0].institutions[0].id	https://openalex.org/I1283582996
authorships[0].institutions[0].ror	https://ror.org/02f9zrr09
authorships[0].institutions[0].type	company
authorships[0].institutions[0].lineage	https://openalex.org/I1283582996
authorships[0].institutions[0].country_code	CH
authorships[0].institutions[0].display_name	Novartis (Switzerland)
authorships[0].author_position	first
authorships[0].raw_author_name	Dominic Brittain
authorships[0].is_corresponding	True
authorships[0].raw_affiliation_strings	Novartis Pharma AG, Basel, Switzerland
authorships[1].author.id	https://openalex.org/A5068771168
authorships[1].author.orcid	https://orcid.org/0000-0001-9831-1568
authorships[1].author.display_name	Peter D’Andrea
authorships[1].countries	US
authorships[1].affiliations[0].institution_ids	https://openalex.org/I4210117619
authorships[1].affiliations[0].raw_affiliation_string	Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
authorships[1].institutions[0].id	https://openalex.org/I4210117619
authorships[1].institutions[0].ror	https://ror.org/028fhxy95
authorships[1].institutions[0].type	company
authorships[1].institutions[0].lineage	https://openalex.org/I1283582996, https://openalex.org/I4210117619
authorships[1].institutions[0].country_code	US
authorships[1].institutions[0].display_name	Novartis (United States)
authorships[1].author_position	middle
authorships[1].raw_author_name	Peter D’Andrea
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
authorships[2].author.id	https://openalex.org/A5086474359
authorships[2].author.orcid
authorships[2].author.display_name	Emilie Gruen
authorships[2].countries	CH
authorships[2].affiliations[0].institution_ids	https://openalex.org/I1283582996
authorships[2].affiliations[0].raw_affiliation_string	Novartis Pharma AG, Basel, Switzerland
authorships[2].institutions[0].id	https://openalex.org/I1283582996
authorships[2].institutions[0].ror	https://ror.org/02f9zrr09
authorships[2].institutions[0].type	company
authorships[2].institutions[0].lineage	https://openalex.org/I1283582996
authorships[2].institutions[0].country_code	CH
authorships[2].institutions[0].display_name	Novartis (Switzerland)
authorships[2].author_position	middle
authorships[2].raw_author_name	Emilie Gruen
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Novartis Pharma AG, Basel, Switzerland
authorships[3].author.id	https://openalex.org/A5063250580
authorships[3].author.orcid	https://orcid.org/0000-0001-6848-3713
authorships[3].author.display_name	Motoi Hosoe
authorships[3].countries	CH
authorships[3].affiliations[0].institution_ids	https://openalex.org/I1283582996
authorships[3].affiliations[0].raw_affiliation_string	Novartis Pharma AG, Basel, Switzerland
authorships[3].institutions[0].id	https://openalex.org/I1283582996
authorships[3].institutions[0].ror	https://ror.org/02f9zrr09
authorships[3].institutions[0].type	company
authorships[3].institutions[0].lineage	https://openalex.org/I1283582996
authorships[3].institutions[0].country_code	CH
authorships[3].institutions[0].display_name	Novartis (Switzerland)
authorships[3].author_position	middle
authorships[3].raw_author_name	Motoi Hosoe
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Novartis Pharma AG, Basel, Switzerland
authorships[4].author.id	https://openalex.org/A5101684065
authorships[4].author.orcid	https://orcid.org/0000-0002-1596-0405
authorships[4].author.display_name	DK Jain
authorships[4].countries	CH
authorships[4].affiliations[0].institution_ids	https://openalex.org/I1283582996
authorships[4].affiliations[0].raw_affiliation_string	Novartis Pharma AG, Basel, Switzerland
authorships[4].institutions[0].id	https://openalex.org/I1283582996
authorships[4].institutions[0].ror	https://ror.org/02f9zrr09
authorships[4].institutions[0].type	company
authorships[4].institutions[0].lineage	https://openalex.org/I1283582996
authorships[4].institutions[0].country_code	CH
authorships[4].institutions[0].display_name	Novartis (Switzerland)
authorships[4].author_position	middle
authorships[4].raw_author_name	Devendra Jain
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Novartis Pharma AG, Basel, Switzerland
authorships[5].author.id	https://openalex.org/A5111480101
authorships[5].author.orcid
authorships[5].author.display_name	Juergen Jauernig
authorships[5].countries	CH
authorships[5].affiliations[0].institution_ids	https://openalex.org/I1283582996
authorships[5].affiliations[0].raw_affiliation_string	Novartis Pharma AG, Basel, Switzerland
authorships[5].institutions[0].id	https://openalex.org/I1283582996
authorships[5].institutions[0].ror	https://ror.org/02f9zrr09
authorships[5].institutions[0].type	company
authorships[5].institutions[0].lineage	https://openalex.org/I1283582996
authorships[5].institutions[0].country_code	CH
authorships[5].institutions[0].display_name	Novartis (Switzerland)
authorships[5].author_position	middle
authorships[5].raw_author_name	Juergen Jauernig
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	Novartis Pharma AG, Basel, Switzerland
authorships[6].author.id	https://openalex.org/A5041873031
authorships[6].author.orcid
authorships[6].author.display_name	Abhijit Pethe
authorships[6].countries	US
authorships[6].affiliations[0].institution_ids	https://openalex.org/I4210117619
authorships[6].affiliations[0].raw_affiliation_string	Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
authorships[6].institutions[0].id	https://openalex.org/I4210117619
authorships[6].institutions[0].ror	https://ror.org/028fhxy95
authorships[6].institutions[0].type	company
authorships[6].institutions[0].lineage	https://openalex.org/I1283582996, https://openalex.org/I4210117619
authorships[6].institutions[0].country_code	US
authorships[6].institutions[0].display_name	Novartis (United States)
authorships[6].author_position	middle
authorships[6].raw_author_name	Abhijit Pethe
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
authorships[7].author.id	https://openalex.org/A5086438198
authorships[7].author.orcid	https://orcid.org/0000-0003-4601-1170
authorships[7].author.display_name	Emil Scosyrev
authorships[7].countries	US
authorships[7].affiliations[0].institution_ids	https://openalex.org/I4210117619
authorships[7].affiliations[0].raw_affiliation_string	Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
authorships[7].institutions[0].id	https://openalex.org/I4210117619
authorships[7].institutions[0].ror	https://ror.org/028fhxy95
authorships[7].institutions[0].type	company
authorships[7].institutions[0].lineage	https://openalex.org/I1283582996, https://openalex.org/I4210117619
authorships[7].institutions[0].country_code	US
authorships[7].institutions[0].display_name	Novartis (United States)
authorships[7].author_position	middle
authorships[7].raw_author_name	Emil Scosyrev
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
authorships[8].author.id	https://openalex.org/A5045876848
authorships[8].author.orcid	https://orcid.org/0000-0003-4987-9434
authorships[8].author.display_name	Ana-Maria Tanase
authorships[8].countries	CH
authorships[8].affiliations[0].institution_ids	https://openalex.org/I1283582996
authorships[8].affiliations[0].raw_affiliation_string	Novartis Pharma AG, Basel, Switzerland
authorships[8].institutions[0].id	https://openalex.org/I1283582996
authorships[8].institutions[0].ror	https://ror.org/02f9zrr09
authorships[8].institutions[0].type	company
authorships[8].institutions[0].lineage	https://openalex.org/I1283582996
authorships[8].institutions[0].country_code	CH
authorships[8].institutions[0].display_name	Novartis (Switzerland)
authorships[8].author_position	middle
authorships[8].raw_author_name	Ana-Maria Tanase
authorships[8].is_corresponding	False
authorships[8].raw_affiliation_strings	Novartis Pharma AG, Basel, Switzerland
authorships[9].author.id	https://openalex.org/A5110770237
authorships[9].author.orcid
authorships[9].author.display_name	Hanns-Christian Tillmann
authorships[9].countries	CH
authorships[9].affiliations[0].institution_ids	https://openalex.org/I1283582996, https://openalex.org/I4400600974
authorships[9].affiliations[0].raw_affiliation_string	Novartis Institutes for Biomedical Research, Translational Medicine, Basel, Switzerland
authorships[9].institutions[0].id	https://openalex.org/I4400600974
authorships[9].institutions[0].ror	https://ror.org/053gv2m95
authorships[9].institutions[0].type	funder
authorships[9].institutions[0].lineage	https://openalex.org/I1283582996, https://openalex.org/I4400600974
authorships[9].institutions[0].country_code
authorships[9].institutions[0].display_name	Novartis Institutes for BioMedical Research
authorships[9].institutions[1].id	https://openalex.org/I1283582996
authorships[9].institutions[1].ror	https://ror.org/02f9zrr09
authorships[9].institutions[1].type	company
authorships[9].institutions[1].lineage	https://openalex.org/I1283582996
authorships[9].institutions[1].country_code	CH
authorships[9].institutions[1].display_name	Novartis (Switzerland)
authorships[9].author_position	last
authorships[9].raw_author_name	Hanns-Christian Tillmann
authorships[9].is_corresponding	False
authorships[9].raw_affiliation_strings	Novartis Institutes for Biomedical Research, Translational Medicine, Basel, Switzerland
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://link.springer.com/content/pdf/10.1007/s12325-021-02025-w.pdf
open_access.oa_status	hybrid
open_access.any_repository_has_fulltext	False
created_date	2022-01-26T00:00:00
display_name	A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
has_fulltext	True
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10051
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	1.0
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2737
primary_topic.subfield.display_name	Physiology
primary_topic.display_name	Asthma and respiratory diseases
related_works	https://openalex.org/W3014131083, https://openalex.org/W3183627703, https://openalex.org/W3014501399, https://openalex.org/W2253786685, https://openalex.org/W4223574756, https://openalex.org/W3212489619, https://openalex.org/W4213355515, https://openalex.org/W3040828970, https://openalex.org/W3093570938, https://openalex.org/W3190448963
cited_by_count	11
counts_by_year[0].year	2025
counts_by_year[0].cited_by_count	2
counts_by_year[1].year	2023
counts_by_year[1].cited_by_count	7
counts_by_year[2].year	2022
counts_by_year[2].cited_by_count	2
locations_count	2
best_oa_location.id	doi:10.1007/s12325-021-02025-w
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S27230875
best_oa_location.source.issn	0741-238X, 1865-8652
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l	0741-238X
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Advances in Therapy
best_oa_location.source.host_organization	https://openalex.org/P4310320330
best_oa_location.source.host_organization_name	Adis, Springer Healthcare
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310320330
best_oa_location.license	cc-by-nc
best_oa_location.pdf_url	https://link.springer.com/content/pdf/10.1007/s12325-021-02025-w.pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id	https://openalex.org/licenses/cc-by-nc
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Advances in Therapy
best_oa_location.landing_page_url	https://doi.org/10.1007/s12325-021-02025-w
primary_location.id	doi:10.1007/s12325-021-02025-w
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S27230875
primary_location.source.issn	0741-238X, 1865-8652
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	0741-238X
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Advances in Therapy
primary_location.source.host_organization	https://openalex.org/P4310320330
primary_location.source.host_organization_name	Adis, Springer Healthcare
primary_location.source.host_organization_lineage	https://openalex.org/P4310320330
primary_location.license	cc-by-nc
primary_location.pdf_url	https://link.springer.com/content/pdf/10.1007/s12325-021-02025-w.pdf
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id	https://openalex.org/licenses/cc-by-nc
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Advances in Therapy
primary_location.landing_page_url	https://doi.org/10.1007/s12325-021-02025-w
publication_date	2022-01-24
publication_year	2022
referenced_works	https://openalex.org/W2906504271, https://openalex.org/W2064243251, https://openalex.org/W2161775889, https://openalex.org/W2039206076, https://openalex.org/W1974588488, https://openalex.org/W2107702660, https://openalex.org/W2951567344, https://openalex.org/W2107824293, https://openalex.org/W2031936609, https://openalex.org/W2110689875, https://openalex.org/W2070684490, https://openalex.org/W2120288315, https://openalex.org/W3087961076, https://openalex.org/W3139512702, https://openalex.org/W3183627703, https://openalex.org/W3021086859, https://openalex.org/W2253786685, https://openalex.org/W2163797903, https://openalex.org/W3014530369, https://openalex.org/W2037071948, https://openalex.org/W3032681217, https://openalex.org/W3041578668, https://openalex.org/W2988347799, https://openalex.org/W3042131288, https://openalex.org/W3122385221, https://openalex.org/W2973949318, https://openalex.org/W1898189008
referenced_works_count	27
abstract_inverted_index
cited_by_percentile_year.max	99
cited_by_percentile_year.min	94
corresponding_author_ids	https://openalex.org/A5030207540
countries_distinct_count	2
institutions_distinct_count	10
corresponding_institution_ids	https://openalex.org/I1283582996
citation_normalized_percentile.value	0.80122213
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False